Learn More
BACKGROUND The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard(More)
7520 Background: OPTIMAL demonstrated the superiority of erlotinib (E) vs gemcitabine/carboplatin (G/C) in terms of progression-free survival (PFS), objective response rate (ORR) and tolerability in(More)
  • 1